FDA Grants Accelerated Approval to Tudriqev for Advanced Melanoma After Prior Treatment Failures
"A hard-won victory for patients facing treatment-resistant melanoma, Tudriqev offers a new injection-based immunotherapy option, marking a significant step forward after overcoming regulatory hurdles." The U.S. Food and Drug Administration…